Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: Behavioral and biochemical evidence

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

“…171 Similarly, sesamol-loaded SLN also showed excellent hepatoprotection along with lower irritation when administered through oral delivery. 20,21,95,172 However, many phytocompounds that have shown excellent hepatoprotection have not yet been studied for their efficacy and bioavailability through SLN or MSLN delivery systems.…”

“…[92][93][94][95][96] Initially, SLN-or MSLN-loaded bioactive compounds were given intranasally or intravenously, and these showed extensive bioavailability in the brain, thereby preventing inflammation and further progression of AD. [97][98][99][100][101] Quercetin-loaded SLN with a particle size of about 200 nm was studied for its efficacy in the AD model, and it showed excellent delivery of quercetin to the brain with a higher antioxidative effect in brain cells.…”

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models

“…72,[77][78][79][80][81] The mobility of the bioactive compound is greatly reduced with a solid lipid core, so it remains in the gut, which enhances the sustained release of the compound for a prolonged period of time. Various methods have been used to develop solid lipid nanoparticles, including multiple emulsion, high-pressure homogenization, and ultrasonication.…”

“…9,11,60,66,[149][150][151] Nanosizing of phytobioactive compounds along with suitable protective agents enhances the bioavailability of the compound to the brain. 24,72,95,145,152 A few of the bioactive nanosize compounds with enhanced bioactivity and less toxicity are discussed in this section. Some of these nanobioactive compounds are listed in Table 1.…”

“…16,29,35 Nanosized bioactive compounds vary in the size from 10 to 1,000 nm, which increases bioactivity and target specificity, reduces toxicity, and enhances safety. 17,29,33,34,68,72,73 The most important characteristics of nanoparticles delivered to the PD brain include the size of the bioactive compound, surface activity, and carrier toxicity. 17,33,73 Figure 1 Nano phytobioactive compounds mechanism of action against Parkinson's disease pathway.…”